Laser therapy is safe and effective for hypertrophic scar management.
The top five dermatology-related issues that physicians and patients should question have been released by the American Academy of Dermatology (AAD) as part of the Choosing Wisely campaign.
BTG plc announced that the FDA has approved Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system.
Young adult men who are unemployed for long periods have shorter telomeres, a sign of accelerated biological aging.
Three-dimensional (3D) high precision surface imaging can be used to monitor changes in the area and volume of port wine stains following laser treatment.
Amgen announced interim overall survival (OS) results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Valeant announced that the New Drug Application for Luzu (luliconazole) Cream, 1% has been approved by the FDA.
The FDA is requesting label and packaging changes to improve the safety of certain over-the-counter (OTC) topical antiseptic products.
Visual evidence in identical twins shows that smoking hastens facial aging, particularly in the middle and lower thirds of the face.
Monitoring changes in a biomarker can predict whether a class of melanomas will be sensitive to a particular class of drugs.
Fractional CO2 laser treatment is safe and seems effective for atrophic acne scars.
Moderate or severe psoriasis is associated with chronic kidney disease.
Good cosmetic outcomes are possible using fractionated ablative carbon dioxide laser therapy for mild-to-moderate cases of rhinophyma.
Antares Pharma announced that the FDA has approved Otrexup injection, the first SC methotrexate for once-weekly self-administration with an easy-to-use, single-dose, disposable auto-injector.
Patients with cutaneous malignant melanoma (CMM) may actually increase their exposure to ultraviolet radiation in the first three years after diagnosis.
There is a slight increased risk of rosacea among females with migraines.
Phototherapy with ultraviolet (UV) A1 radiation induces a reduction in serum 25-hydroxyvitamin D3 (25[OH]D) levels, whereas narrowband UVB (UVBnb) and UVA/UVBnb induces significant increases in serum 25(OH)D.
Low-level laser therapy (LLLT) seems to be effective and safe for hair growth in men and women.
The effects of appearance-enhancing procedures such as neuromodulators, fillers, and light or laser treatments have lasting effects and can rarely be used "too early".
Botox Cosmetic has been approved for an additional indication to temporarily treat moderate-to-severe crow's feet lines.
Physicians very rarely educate patients regarding the use of sunscreen and sun-protective behaviors.
MNK-795 (Mallinckrodt) achieved the primary endpoint in a Phase 3 efficacy trial for the treatment of moderate to severe acute pain following bunionectomy.
The FDA has approved Galderma's Mirvaso (brimonidine) topical gel for the topical treatment of the facial erythema associated with rosacea in adults 18 years or older.
Vitamin D may influence atopic dermatitis, and supplementation is associated with reduced disease severity.
The FDA has approved marketing of bioMerieux Inc.'s VITEK MS, the first mass spectrometer system for automated identification of 193 different microorganisms known to cause serious illness in humans.
For premenopausal women, sleep quality is associated with skin function and aging.
Nontreatment and undertreatment of psoriasis and psoriatic arthritis, including severe disease, is widespread in the United States.
For patients with psoriasis, major medical comorbidity increases with increasing severity of disease.
Several subgroups of patients with cutaneous lupus erythematosus (CLE) are deficient in their use of photoprotection
Merz announced that the FDA has approved Naftin Gel 2% for the treatment of interdigital-type tinea pedis.
Delayed primary skin closure may reduce the risk of infection after surgery, but the current studies are not definitive due to poor design.
Warner Chilcott announced the availability of a new 200mg dosage strength for Doryx (doxycycline hyclate) delayed-release tablets.
Exposure to antibiotics in the first year of life is associated with an increased likelihood of eczema, with increasing risk seen for each additional course of antibiotics.
ConvaTec has launched Aquacel Ag Foam dressing, the latest addition to the Aquacel family of wound management products.
Daily sunscreen use can slow skin aging in middle-aged adults.
Overweight patients with psoriasis have reduced disease severity and improved skin-related quality of life after weight loss.
Comorbid conditions often accompany alopecia areata.
Sandoz is recalling two lots of Methotrexate Sodium injectable after discovering particulate matter in the vials.
Twitter can teach health care providers about popular health-related beliefs regarding acne.
A somatic single nucleotide mutation causes Sturge-Weber syndrome and port wine stains.
The U.S. FDA has proposed an order to reclassify sunlamp products from a low-risk to a moderate-risk device, which would require comprehensive risk labeling on such products.
SD-101 was granted Breakthrough Therapy designation for the treatment of skin blisters and erosions caused by Epidermolysis Bullosa.
The American Academy of Pediatrics has reviewed and endorsed the recommendations of the American Acne and Rosacea Society for the clinical management of pediatric acne.
Aurstat Anti-Itch Hydrogel, a non-steroidal treatment from Onset Dermatologics, provides relief of pain, burning, and itching associated with various dermatoses.
The FDA has granted Orphan Drug designation to Teva Pharmaceutical and Xenon Pharmaceutical's investigation drug XEN402, which is being developed for the treatment of pain associated with erythromelalgia.
For schoolchildren, exposure to human papillomavirus (HPV)-causing warts in the family and school class is associated with an increased risk of wart development.
The relative proportion of methicillin-resistant Staphylococcus aureus (MRSA) is increasing in S. aureus isolates, and methicillin-sensitive S. aureus (MSSA) is becoming increasingly resistant to antibiotics.
Taro Pharmaceuticals has received FDA approval for its New Drug Application for Topicort Topical Spray, a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years and older.
The FDA has granted Fast Track designation to Elorac's naloxone topical lotion, an opiate antagonist with no agonist activity, for the relief of pruritus in patients with cutaneous T-cell lymphoma.
Allegra Anti-Itch Cooling Relief Cream and Allegra Anti-Itch Intensive Relief Cream have been released. Each cream provides itch relief from reactions to skin irritations for patients 2 years and older.
Male vertex baldness is associated with an increased risk of coronary heart disease, with the association depending on the severity of baldness.
There is some evidence that supplementation with a prebiotic may prevent eczema in formula-fed infants, but more research is needed before routine use of prebiotics can be recommended.
Upsher-Smith has launched its latest skin care product, AmLactin Cerapeutic Restoring Body Lotion. The lotion contains alpha-hydroxy acids, which are effective at exfoliating and hydrating the skin, as well as three skin identical ceramides, which strengthen the skin's protective moisture barrier.
Psoriasis is significantly tied to an increased risk of new-onset diabetes mellitus, according to a new study.
Handheld umbrellas are effective at blocking ultraviolet radiation. The poorest performing umbrella still blocked an average of 77% UVR, according to researchers.
SilvrSTAT Antibacterial Wound Dressing Gel , from ABL Medical, manages 1st and 2nd-degree burns, stasis ulcers, pressure ulcers, diabetic ulcers, lacerations, abrasions, skin tears, surgical incision sites, device insertion site wounds, and graft and donor sites. SilvrSTAT is available in 1oz or 3oz tubes.
Specific strains of the skin commensal Propionibacterium acnes are associated with acne and with healthy skin.
Kythera Biopharmaceuticals announced positive interim results from a Phase 3b study (ATX-101-11-26) to evaluate the safety and efficacy of ATX-101, an investigational injectable drug for the reduction of unwanted submental fat (SMF), also known as double chin.
Skin changes, including new rash, new growths, discoloration, and changes in texture, could be among the first signs indicating an underlying medical condition.
Complications linked to tattoos and tattoo inks include allergic reactions, serious infections, and reactions that can be mistaken for skin cancer.
Evidence suggests that there may be a connection between acne and diet, particularly foods with a high glycemic index.
Among women of reproductive age, isotretinoin is not associated with an increased risk for inflammatory bowel disease (IBD), including ulcerative colitis (UC) or Crohn's disease (CD).
Antares Pharma announced that the FDA has accepted for review their New Drug Application (NDA) for Otrexup, a potential new product for the SQ delivery of methotrexate (MTX) using Medi-Jet technology.
Galderma Laboratories announced that the FDA has approved Epiduo (adapalene and benzoyl peroxide) Gel for the treatment of acne in children as young as 9 years old.
Galderma announced that Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) cream is available again for short-term treatment (up to 8 weeks) of moderate to severe melasma of the face, in the presence of measures for sun avoidance, including the use of sunscreens.
Doctors who treat patients with psoriasis show wide variation in their beliefs about the safety and effectiveness of psoriasis treatments.
Eating fast food ≥3 times per week is associated with an increased risk of severe asthma, rhinoconjunctivitis, and eczema among children and adolescents, while eating fruit seems to be protective against severe asthma.
Uluru announced that Altrazeal Blister Pack is now available for the treatment of chronic wounds.
For patients with facial photodamage and actinic keratoses (AK), treatment with a new fractional resurfacing technique that uses a 1927-nm nonablative thulium laser reduces the number of facial AK and produces noticeable improvement in overall photodamage.
Despite considerable controversy surrounding the third interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I), which indicate a benefit of sentinel lymph node biopsy (SLNB) on disease-free survival in melanoma, the procedure is carried out routinely.
Oral methotrexate provides a lasting benefit for most patients with juvenile localized scleroderma (JLS).
Celgene announced results from the ESTEEM 1 & 2 pivotal Phase 3 studies, evaluating apremilast in patients with moderate to severe chronic plaque psoriasis.
Improved understanding of the pathogenesis of infantile hemangiomas (IHs) is leading to better treatment options.
While the majority of dermatologists feel capable of diagnosing psychocutaneous disease, most are also uncomfortable starting antidepressants or antipsychotics and feel unsuccessful in treating these conditions.
For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment with once-weekly adalimumab is associated with improvements in pain and inflammation.
Antares Pharma announced the submission of a New Drug Application (NDA) to the FDA for Otrexup for the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and moderate to severe psoriasis.
Family history, body mass index, and diet are all linked to the risk of moderate-to-severe acne in young adults.
Naterra announced the launch of Phase+, a skin care line designed to address the cosmetic effects for patients with diabetes.
Eccrine sweat glands, the most abundant appendage in human skin, unique to some primates, play a role in wound repair.
Ranbaxy Laboratories announced the launch of Absorica (isotretinoin) capsules, a product licensed from Cipher Pharmaceuticals.
Valeant Pharmaceuticals announced positive results from two pivotal studies evaluating efinaconazole 10% topical solution in 1,655 subjects with onychomycosis.
Children with psoriasis are more likely to be obese, particularly if they have severe disease or live in the United States.
A new material that can self-heal and is pressure- and flexion-sensitive could be used as an electronic skin.
Re-excision of mildly or moderately histologically dysplastic nevi (HDN) that approach a microscopic border may not be necessary, as favorable long-term outcomes are achieved without re-excision.
Multiple sessions of fractional laser treatment with erbium:yttrium-aluminum-garnet (Er:YAG) for facial resurfacing are comparable to a single ablative Er:YAG laser treatment.
The use of actigraphy to record movement as an objective surrogate for eczema activity is of limited use.
A single 10-minute, at-home treatment with topical ivermectin lotion eliminates head lice infestations in nearly all patients by the next day.
Fascia lata, which is a thin, pliable, and vascularized tissue, can be effectively used as a substitute for nasal lining in complex total and subtotal nasal reconstruction procedures.
LEO Pharma announced that the FDA has approved Taclonex Topical Suspension (calcipotriene and betamethasone dipropionate), 0.005%/0.064% for the treatment of body plaque psoriasis for up to 8 weeks in patients ≥18 years.
A handheld nonablative fractional laser is safe and seems effective for home use for treating periorbital wrinkles.
Nuvo Research and Galderma Laboratories announced that the FDA has approved a supplemental New Drug Application (sNDA) for Pliaglis (lidocaine/tetracaine) 7%/7% Cream for use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures (eg, dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal).
Quadex Labs announced the release of Viroxyn Professional Use (benzocaine 7.5%, benzalkonium chloride 0.13%), a single application cold sore product available exclusively through healthcare professionals.
Patients with localized scleroderma (morphea) often experience delay in diagnosis and variability in treatment that is based more on the specialty of the provider than disease characteristics.
Both atopic dermatitis (AD) and loss-of-function mutations in the filaggrin gene (FLG) are independently associated with an increased risk of developing chronic irritant contact dermatitis (ICD), with people having both mutations at about a five-fold higher risk.
Patients with rapidly progressive alopecia areata (RPAA) tend to show favorable prognosis regardless of treatment selected.
Stiefel, a GlaxoSmithKline company, announced that the FDA has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) foam, 0.005%. The expanded indication now includes the topical treatment of plaque psoriasis of the scalp in patients aged >18 years.
Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial infarction, and stroke.
Bacteriophages that infect the dominant bacteria inhabitant of the human sebaceous follicle, Propionibacterium acnes (P. acnes), which contributes to the pathogenesis of acne, have limited genetic diversity and display a broad host range
Avidas Pharmaceuticals announced the availability of Avidoxy (doxycycline tablets) and Avidoxy DK combination kit through Cardinal Health.
Protease-activated receptor 2 (PAR-2), which is activated by cowhage, may play a role in central centrifugal cicatricial alopecia (CCCA), the most common cause of scarring hair loss in African-American women.